BACKGROUND: The aim of this study was to report our incidence of clinically evident neck recurrence, salvage neck management and subsequent outcomes in patients with papillary thyroid cancer. This is important to know so that patients with thyroid cancer can be properly counselled about the implications of recurrent disease and subsequent outcome. METHODS: An institutional database of 3664 patients with thyroid cancer operated between 1986 and 2010 was reviewed. Patients with nonpapillary histology and gross residual disease and those with distant metastases at presentation or distant metastases prior to nodal recurrence were excluded from the study. Of these, 99 (3.0%) patients developed clinically evident nodal recurrence. Details of recurrence and subsequent therapy were recorded for each patient. Subsequent disease-specific survival (sDSS), distant recurrence-free survival (sDRFS) and nodal recurrence-free survival (sNRFS) were determined from the date of first nodal recurrence using the Kaplan-Meier method. RESULTS: Of the 99 patients, 59% were female and 41% male. The median age was 41 years (range 5-91). The majority of patients had pT3/4 primary tumours (63%) and were pN+ (78%) at initial presentation. The median time to clinically evident nodal recurrence was 28 months (range: 3-264). Nodal recurrence occurred in the central neck in 15 (15%) patients, lateral neck in 74 (75%) patients and both in 10 (10%) patients. After salvage treatment, the 5-year sDSS was 97.4% from time of nodal recurrence. The 5-year sDRFS and sNRFS were 89.2% and 93.7%, respectively. CONCLUSION: In our series, isolated clinically evident nodal recurrence occurred in 3.0% of patients. Such patients are successfully salvaged with surgery and adjuvant therapy with sDSS of 97.4% at 5 years.
BACKGROUND: The aim of this study was to report our incidence of clinically evident neck recurrence, salvage neck management and subsequent outcomes in patients with papillary thyroid cancer. This is important to know so that patients with thyroid cancer can be properly counselled about the implications of recurrent disease and subsequent outcome. METHODS: An institutional database of 3664 patients with thyroid cancer operated between 1986 and 2010 was reviewed. Patients with nonpapillary histology and gross residual disease and those with distant metastases at presentation or distant metastases prior to nodal recurrence were excluded from the study. Of these, 99 (3.0%) patients developed clinically evident nodal recurrence. Details of recurrence and subsequent therapy were recorded for each patient. Subsequent disease-specific survival (sDSS), distant recurrence-free survival (sDRFS) and nodal recurrence-free survival (sNRFS) were determined from the date of first nodal recurrence using the Kaplan-Meier method. RESULTS: Of the 99 patients, 59% were female and 41% male. The median age was 41 years (range 5-91). The majority of patients had pT3/4 primary tumours (63%) and were pN+ (78%) at initial presentation. The median time to clinically evident nodal recurrence was 28 months (range: 3-264). Nodal recurrence occurred in the central neck in 15 (15%) patients, lateral neck in 74 (75%) patients and both in 10 (10%) patients. After salvage treatment, the 5-year sDSS was 97.4% from time of nodal recurrence. The 5-year sDRFS and sNRFS were 89.2% and 93.7%, respectively. CONCLUSION: In our series, isolated clinically evident nodal recurrence occurred in 3.0% of patients. Such patients are successfully salvaged with surgery and adjuvant therapy with sDSS of 97.4% at 5 years.
Authors: Gary L Clayman; Garima Agarwal; Beth S Edeiken; Steven G Waguespack; Dianna B Roberts; Steven I Sherman Journal: Thyroid Date: 2011-12 Impact factor: 6.568
Authors: Mark L Urken; Mira Milas; Gregory W Randolph; Ralph Tufano; Donald Bergman; Victor Bernet; Elise M Brett; James D Brierley; Rhoda Cobin; Gerard Doherty; Joshua Klopper; Stephanie Lee; Josef Machac; Jeffrey I Mechanick; Lisa A Orloff; Douglas Ross; Robert C Smallridge; David J Terris; Jason B Clain; Michael Tuttle Journal: Head Neck Date: 2014-04-03 Impact factor: 3.147
Authors: Kathryn G Schuff; Stephen M Weber; Babak Givi; Mary H Samuels; Peter E Andersen; James I Cohen Journal: Laryngoscope Date: 2008-05 Impact factor: 3.325
Authors: Ralph P Tufano; Gary Clayman; Keith S Heller; William B Inabnet; Electron Kebebew; Ashok Shaha; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2015-01 Impact factor: 6.568
Authors: N Chereau; T O Oyekunle; A Zambeli-Ljepović; H S Kazaure; S A Roman; F Menegaux; J A Sosa Journal: Br J Surg Date: 2019-04-23 Impact factor: 6.939
Authors: Maria Papaleontiou; Josh M Evron; Nazanene H Esfandiari; David Reyes-Gastelum; Kevin C Ward; Ann S Hamilton; Francis Worden; Megan R Haymart Journal: Thyroid Date: 2020-04-16 Impact factor: 6.568
Authors: Samuel Chan; Katarina Karamali; Anna Kolodziejczyk; Georgios Oikonomou; John Watkinson; Vinidh Paleri; Iain Nixon; Dae Kim Journal: Eur Thyroid J Date: 2020-01-28
Authors: Nathan Y Yu; Aditya Khurana; Daniel J Ma; Michelle A Neben-Wittich; Michael A Golafshar; Lisa A McGee; Jean-Claude M Rwigema; Robert L Foote; Samir H Patel Journal: Int J Part Ther Date: 2021-06-25